TDMS Study 05044-01 Pathology Tables
INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
4-VINYL-1-CYCLOHEXENE DIEPOXIDE
NTP Experiment-Test: 05044-01 Report: PEIRPT03
Study Type: CHRONIC Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:13
Facility: Battelle Columbus Laboratory
Chemical CAS #: 106-87-6
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05044-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:13
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 60 60 60
Scheduled Sacrifice 10 10 10
Early Deaths
Dead 8 13 21
Moribund 15 14 14
Survivors
Terminal Sacrifice 27 23 15
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (46) (47) (45)
Parasite Metazoan 1 (2%) 1 (2%)
Intestine Large, Colon (47) (50) (48)
Inflammation, Suppurative 1 (2%)
Parasite Metazoan 1 (2%) 3 (6%)
Intestine Large, Rectum (48) (48) (48)
Inflammation, Suppurative 1 (2%)
Parasite Metazoan 5 (10%) 7 (15%) 4 (8%)
Intestine Small, Duodenum (50) (49) (49)
Inflammation, Acute, Necrotizing 1 (2%)
Intestine Small, Ileum (47) (44) (42)
Inflammation, Acute, Necrotizing 1 (2%)
Liver (50) (50) (50)
Angiectasis 1 (2%)
Basophilic Focus 38 (76%) 32 (64%) 35 (70%)
Clear Cell Focus 2 (4%)
Degeneration, Cystic 1 (2%)
Eosinophilic Focus 1 (2%)
Fatty Change 9 (18%) 5 (10%) 1 (2%)
Hepatodiaphragmatic Nodule 3 (6%) 2 (4%) 3 (6%)
Hyperplasia, Focal 1 (2%)
Inflammation, Acute, Necrotizing 1 (2%) 1 (2%) 2 (4%)
Inflammation, Chronic Active 4 (8%) 2 (4%)
Bile Duct, Hyperplasia 7 (14%) 10 (20%) 14 (28%)
Centrilobular, Necrosis 5 (10%) 5 (10%) 1 (2%)
Hepatocyte, Regeneration 1 (2%)
Mesentery (4) (2)
Inflammation, Acute, Necrotizing 1 (25%)
Inflammation, Chronic Active 3 (75%)
Artery, Inflammation, Chronic Active 1 (50%)
Pancreas (48) (47) (48)
Focal Cellular Change 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 05044-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:13
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Inflammation, Acute 1 (2%)
Inflammation, Chronic Active 2 (4%) 1 (2%)
Metaplasia 1 (2%)
Acinus, Atrophy 19 (40%) 17 (36%) 17 (35%)
Acinus, Hyperplasia 1 (2%)
Pharynx (1) (1)
Inflammation, Suppurative 1 (100%)
Salivary Glands (50) (50) (50)
Atrophy 1 (2%) 1 (2%)
Focal Cellular Change 1 (2%)
Inflammation, Suppurative 1 (2%)
Necrosis 1 (2%)
Duct, Inflammation, Chronic Active 1 (2%)
Stomach, Forestomach (50) (48) (50)
Inflammation, Chronic Active 2 (4%) 3 (6%)
Ulcer 5 (10%)
Epithelium, Hyperplasia 5 (10%) 4 (8%)
Stomach, Glandular (50) (48) (50)
Inflammation, Acute, Necrotizing 4 (8%) 2 (4%) 1 (2%)
Inflammation, Chronic Active 2 (4%)
Mineralization 1 (2%)
Tooth (2) (1) (2)
Dysplasia 1 (50%)
Gingiva, Hyperplasia, Squamous 1 (50%)
Peridontal Tissue, Inflammation, Suppurative 1 (50%) 1 (100%) 1 (50%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50)
Degeneration, Chronic 45 (90%) 40 (80%) 35 (70%)
Inflammation, Suppurative 1 (2%)
Mineralization 1 (2%)
Atrium, Thrombosis 2 (4%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (48) (50)
Hyperplasia 38 (76%) 29 (60%) 34 (68%)
Hypertrophy 4 (8%) 1 (2%) 2 (4%)
Necrosis 1 (2%) 1 (2%)
Vacuolization Cytoplasmic 1 (2%) 1 (2%) 1 (2%)
Adrenal Gland, Medulla (50) (48) (50)
Hyperplasia 9 (18%) 10 (21%) 6 (12%)
Islets, Pancreatic (48) (48) (48)
Hyperplasia 2 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 05044-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:13
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Parathyroid Gland (47) (43) (48)
Hyperplasia 1 (2%)
Pituitary Gland (47) (49) (48)
Cyst 1 (2%)
Pars Distalis, Degeneration, Focal 1 (2%)
Pars Distalis, Hyperplasia 19 (40%) 20 (41%) 15 (31%)
Thyroid Gland (46) (48) (49)
Inflammation, Chronic Active 1 (2%) 1 (2%)
C-Cell, Hyperplasia 37 (80%) 33 (69%) 23 (47%)
Follicular Cell, Hyperplasia 2 (4%) 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (45) (50) (49)
Hyperplasia 6 (13%) 3 (6%) 4 (8%)
Inflammation, Acute, Necrotizing 1 (2%) 2 (4%)
Inflammation, Chronic Active 8 (18%) 2 (4%) 5 (10%)
Duct, Hyperplasia 1 (2%) 2 (4%)
Ovary (50) (49) (50)
Cyst 4 (8%) 5 (10%) 9 (18%)
Uterus (50) (50) (50)
Dilatation 1 (2%)
Inflammation, Chronic Active 2 (4%)
Prolapse 1 (2%) 1 (2%)
Vagina (3)
Inflammation, Suppurative 3 (100%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (49) (49)
Femoral, Hyperplasia, Reticulum Cell 4 (8%) 5 (10%) 6 (12%)
Femoral, Myelofibrosis 3 (6%) 1 (2%)
Femoral, Necrosis 1 (2%) 1 (2%)
Femoral, Myeloid Cell, Hyperplasia 1 (2%)
Lymph Node (50) (50) (50)
Mediastinal, Hematopoietic Cell Proliferation 1 (2%)
Lymph Node, Mandibular (50) (50) (50)
Hematopoietic Cell Proliferation 1 (2%)
Inflammation, Acute, Necrotizing 1 (2%)
Lymph Node, Mesenteric (3) (2)
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 05044-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:13
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Edema 1 (33%) 1 (50%)
Spleen (50) (50) (49)
Fibrosis 2 (4%) 2 (4%) 1 (2%)
Hematopoietic Cell Proliferation 3 (6%)
Hemorrhage, Chronic 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (49) (50)
Hyperplasia, Cystic 41 (82%) 20 (41%) 37 (74%)
Skin (50) (50) (50)
Inflammation, Acute, Necrotizing 1 (2%)
Inflammation, Chronic Active 1 (2%)
Back, Acanthosis 1 (2%) 4 (8%) 11 (22%)
Back, Sebaceous Gland, Hypertrophy 15 (30%)
Hair Follicle, Inflammation, Chronic 1 (2%)
Scapula, Acanthosis 4 (8%) 33 (66%) 42 (84%)
Scapula, Cyst Epithelial Inclusion 1 (2%)
Scapula, Inflammation, Acute, Necrotizing 1 (2%) 1 (2%) 1 (2%)
Scapula, Inflammation, Chronic Active 1 (2%)
Sebaceous Gland, Scapula, Hypertrophy 1 (2%) 20 (40%) 43 (86%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50)
Cranium, Fibrous Osteodystrophy 1 (2%)
Femur, Fibrous Osteodystrophy 1 (2%)
Mandible, Fibrous Osteodystrophy 1 (2%)
Tarsal, Hyperostosis 1 (2%)
Tarsal, Inflammation, Chronic Active 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50)
Compression 12 (24%) 7 (14%) 5 (10%)
Infarct 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50)
Inflammation, Chronic Active 4 (8%) 4 (8%) 6 (12%)
Mineralization 1 (2%)
Alveolar Epithelium, Hyperplasia 2 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 05044-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:13
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - CONT
Mediastinum, Inflammation, Chronic Active 1 (2%)
Nose (49) (50) (49)
Hyperplasia, Squamous 1 (2%)
Mucosa, Inflammation, Suppurative 2 (4%) 3 (6%)
Mucosa, Thrombosis 2 (4%)
Nasolacrimal Duct, Inflammation, Suppurative 2 (4%) 2 (4%) 3 (6%)
Trachea (50) (50) (49)
Inflammation, Chronic Active 1 (2%)
Metaplasia, Squamous 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (5) (3) (3)
Degeneration 4 (80%) 2 (67%) 2 (67%)
Harderian Gland (2)
Inflammation, Chronic 2 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (49)
Amyloid Deposition 1 (2%)
Bacterium 1 (2%)
Inflammation, Suppurative 1 (2%)
Mineralization 1 (2%)
Nephropathy, Chronic 47 (94%) 45 (90%) 46 (94%)
Cortex, Atrophy, Focal 1 (2%)
Pelvis, Inflammation, Suppurative 1 (2%)
Renal Tubule, Hyperplasia 6 (12%)
Urinary Bladder (50) (50) (48)
Transitional Epithelium, Hyperplasia 1 (2%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 05044-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:13
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 60 60 60
Scheduled Sacrifice 10 10 10
Early Deaths
Moribund 31 37 29
Dead 12 5 16
Drowned 1
Survivors
Terminal Sacrifice 7 8 4
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (50) (49)
Inflammation, Acute, Necrotizing 1 (2%)
Intestine Large, Cecum (45) (48) (40)
Inflammation, Suppurative 1 (2%) 1 (3%)
Parasite Metazoan 1 (2%) 1 (2%) 1 (3%)
Thrombosis 1 (2%)
Intestine Large, Colon (48) (49) (40)
Mineralization 5 (10%) 3 (6%)
Parasite Metazoan 2 (4%) 2 (4%)
Intestine Large, Rectum (48) (48) (44)
Inflammation, Suppurative 1 (2%)
Mineralization 2 (4%) 2 (4%)
Parasite Metazoan 4 (8%) 1 (2%)
Intestine Small, Duodenum (48) (50) (45)
Inflammation, Acute, Necrotizing 4 (8%) 5 (10%) 1 (2%)
Mineralization 1 (2%)
Thrombosis 1 (2%)
Intestine Small, Ileum (44) (49) (37)
Inflammation, Acute, Necrotizing 1 (2%) 1 (2%)
Liver (50) (50) (50)
Basophilic Focus 15 (30%) 15 (30%) 10 (20%)
Degeneration, Cystic 7 (14%) 7 (14%) 3 (6%)
Eosinophilic Focus 1 (2%)
Fatty Change 5 (10%) 6 (12%) 2 (4%)
Hepatodiaphragmatic Nodule 1 (2%) 1 (2%) 1 (2%)
Inflammation, Acute, Necrotizing 3 (6%) 2 (4%)
Inflammation, Chronic Active 1 (2%)
Thrombosis 1 (2%)
Bile Duct, Cyst 1 (2%)
Bile Duct, Hyperplasia 20 (40%) 39 (78%) 19 (38%)
Centrilobular, Necrosis 11 (22%) 9 (18%) 8 (16%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
NTP Experiment-Test: 05044-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:13
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Hepatocyte, Regeneration 1 (2%)
Mesentery (7) (6) (6)
Inflammation, Acute, Necrotizing 1 (14%) 2 (33%)
Inflammation, Chronic Active 2 (29%) 1 (17%)
Artery, Mineralization 4 (57%) 3 (50%) 1 (17%)
Pancreas (50) (50) (45)
Inflammation, Acute 1 (2%)
Inflammation, Chronic Active 1 (2%) 1 (2%)
Acinus, Atrophy 23 (46%) 24 (48%) 19 (42%)
Acinus, Hyperplasia 2 (4%) 1 (2%)
Artery, Mineralization 1 (2%)
Pharynx (2) (2)
Inflammation, Suppurative 1 (50%) 2 (100%)
Salivary Glands (50) (50) (50)
Inflammation, Suppurative 1 (2%)
Necrosis 1 (2%)
Artery, Mineralization 2 (4%)
Stomach, Forestomach (50) (50) (47)
Inflammation, Chronic Active 1 (2%) 10 (20%) 2 (4%)
Mineralization 6 (12%) 3 (6%) 1 (2%)
Ulcer 8 (16%) 6 (12%) 8 (17%)
Epithelium, Hyperplasia 6 (12%) 10 (20%) 2 (4%)
Stomach, Glandular (50) (50) (48)
Inflammation, Acute, Necrotizing 11 (22%) 3 (6%) 5 (10%)
Mineralization 10 (20%) 11 (22%) 4 (8%)
Tooth (2) (5)
Dysplasia 1 (20%)
Peridontal Tissue, Inflammation, Suppurative 2 (100%) 4 (80%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (7) (5) (2)
Aneurysm 1 (20%)
Aorta, Mineralization 7 (100%) 4 (80%) 2 (100%)
Heart (50) (50) (50)
Degeneration, Chronic 45 (90%) 42 (84%) 48 (96%)
Inflammation, Suppurative 2 (4%) 3 (6%)
Mineralization 9 (18%) 7 (14%) 3 (6%)
Atrium, Thrombosis 4 (8%) 3 (6%) 2 (4%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 8
NTP Experiment-Test: 05044-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:13
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (50) (50)
Hyperplasia 23 (46%) 24 (48%) 31 (62%)
Hypertrophy 1 (2%)
Necrosis 3 (6%) 2 (4%)
Vacuolization Cytoplasmic 1 (2%)
Adrenal Gland, Medulla (50) (50) (50)
Hyperplasia 28 (56%) 28 (56%) 20 (40%)
Islets, Pancreatic (50) (50) (46)
Hyperplasia 2 (4%) 1 (2%) 5 (11%)
Parathyroid Gland (49) (45) (45)
Hyperplasia 14 (29%) 14 (31%) 4 (9%)
Hypertrophy 1 (2%)
Pituitary Gland (50) (50) (48)
Pars Distalis, Cyst 1 (2%)
Pars Distalis, Hyperplasia 23 (46%) 10 (20%) 11 (23%)
Pars Distalis, Mineralization 2 (4%) 1 (2%)
Pars Distalis, Necrosis 1 (2%)
Thyroid Gland (48) (50) (43)
Mineralization 1 (2%) 1 (2%)
Pigmentation, Lipofuscin 1 (2%)
C-Cell, Hyperplasia 28 (58%) 30 (60%) 22 (51%)
Follicular Cell, Hyperplasia 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ductus Deferens (2) (1)
Mineralization 2 (100%) 1 (100%)
Epididymis (50) (50) (48)
Mineralization 1 (2%)
Penis (1)
Inflammation, Acute, Necrotizing 1 (100%)
Preputial Gland (49) (49) (50)
Hyperplasia 1 (2%) 3 (6%)
Inflammation, Chronic Active 11 (22%) 16 (33%) 9 (18%)
Duct, Hyperplasia 1 (2%) 1 (2%)
Prostate (49) (50) (50)
Inflammation, Chronic Active 34 (69%) 32 (64%) 41 (82%)
Epithelium, Hyperplasia 1 (2%)
Testes (50) (50) (50)
Cyst 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 9
NTP Experiment-Test: 05044-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:13
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - CONT
Thrombosis 1 (2%)
Interstitial Cell, Hyperplasia 9 (18%) 7 (14%) 14 (28%)
Seminiferous Tubule, Atrophy 9 (18%) 2 (4%) 4 (8%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (49)
Femoral, Myelofibrosis 3 (6%) 1 (2%) 4 (8%)
Lymph Node, Mandibular (50) (49) (50)
Edema 2 (4%)
Inflammation, Acute, Necrotizing 1 (2%)
Lymph Node, Mesenteric (7) (10) (3)
Edema 1 (14%) 4 (40%)
Hemorrhage 1 (10%)
Inflammation, Acute, Necrotizing 1 (10%)
Spleen (50) (50) (49)
Abscess 1 (2%)
Amyloid Deposition 1 (2%)
Fibrosis 8 (16%) 8 (16%) 7 (14%)
Hematopoietic Cell Proliferation 1 (2%) 1 (2%) 1 (2%)
Hemorrhage, Chronic 1 (2%)
Necrosis 3 (6%) 3 (6%)
Thymus (41) (40) (42)
Cyst 1 (2%)
Inflammation, Acute, Necrotizing 1 (3%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (45) (48) (42)
Hyperplasia, Cystic 34 (76%) 25 (52%) 36 (86%)
Mineralization 1 (2%)
Skin (50) (50) (50)
Abscess 2 (4%)
Acanthosis 2 (4%) 1 (2%)
Cyst Epithelial Inclusion, Multiple 1 (2%)
Inflammation, Acute, Necrotizing 3 (6%) 1 (2%) 2 (4%)
Mineralization 1 (2%)
Back, Acanthosis 6 (12%) 8 (16%)
Back, Inflammation, Acute, Necrotizing 1 (2%)
Back, Sebaceous Gland, Hypertrophy 4 (8%) 8 (16%)
Scapula, Acanthosis 39 (78%) 40 (80%)
Scapula, Cyst Epithelial Inclusion 1 (2%) 1 (2%)
Scapula, Hypertrophy 2 (4%)
Scapula, Inflammation, Acute, Necrotizing 1 (2%) 1 (2%)
Sebaceous Gland, Hypertrophy 1 (2%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 10
NTP Experiment-Test: 05044-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:13
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - CONT
Sebaceous Gland, Scapula, Hypertrophy 28 (56%) 39 (78%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50)
Cranium, Fibrous Osteodystrophy 13 (26%) 12 (24%) 4 (8%)
Femur, Fibrous Osteodystrophy 13 (26%) 12 (24%) 4 (8%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (49)
Compression 7 (14%) 7 (14%) 11 (22%)
Infarct 4 (8%) 2 (4%) 3 (6%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50)
Infarct 1 (2%) 1 (2%)
Inflammation, Chronic Active 11 (22%) 15 (30%) 1 (2%)
Mineralization 9 (18%) 7 (14%) 2 (4%)
Thrombosis 1 (2%) 1 (2%)
Alveolar Epithelium, Hyperplasia 3 (6%)
Artery, Mediastinum, Mineralization 3 (6%) 6 (12%)
Mediastinum, Inflammation, Chronic Active 1 (2%)
Pleura, Inflammation, Suppurative 2 (4%)
Nose (50) (50) (49)
Mucosa, Inflammation, Suppurative 21 (42%) 12 (24%) 13 (27%)
Mucosa, Thrombosis 1 (2%) 1 (2%) 3 (6%)
Nasolacrimal Duct, Inflammation, Suppurative 3 (6%) 2 (4%) 4 (8%)
Septum, Necrosis 1 (2%) 1 (2%)
Trachea (50) (49) (48)
Inflammation, Chronic Active 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (7) (3) (6)
Degeneration 3 (43%) 2 (67%) 6 (100%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 11
NTP Experiment-Test: 05044-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 4-VINYL-1-CYCLOHEXENE DIEPOXIDE Date: 09/06/94
Route: DERMAL,SOLUTION Time: 10:15:13
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/ML 50 MG/ML 100 MG/
ML
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (49)
Hydronephrosis 1 (2%)
Mineralization 9 (18%) 7 (14%) 5 (10%)
Nephropathy, Chronic 50 (100%) 49 (98%) 49 (100%)
Pelvis, Inflammation, Suppurative 2 (4%) 5 (10%) 4 (8%)
Renal Tubule, Cytoplasmic Alteration 2 (4%)
Renal Tubule, Hyperplasia 2 (4%) 6 (12%) 4 (8%)
Renal Tubule, Necrosis 1 (2%)
Urethra (1)
Inflammation, Suppurative 1 (100%)
Urinary Bladder (49) (50) (49)
Hemorrhage 1 (2%) 1 (2%)
Inflammation, Suppurative 2 (4%)
Mineralization 2 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 78027-78027/78027
--multipart-boundary--